Market Place
Sourcing Support
Amicus: UK Prix Galien For Pombiliti+Opfolda As Best Pharma Product
04 Jun 2024 //
GLOBENEWSWIRE
PANTHERx®Rare Selected by Edenbridge as Specialty Pharmacy for Yargesa
01 Apr 2024 //
PR NEWSWIRE
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti
08 Feb 2024 //
GLOBENEWSWIRE
Amicus` muscle disorder therapy gets FDA nod but restricted label drags shares
29 Sep 2023 //
REUTERS
Amicus Announces Approval and Launch of New Pompe Disease Therapy in UK
16 Aug 2023 //
BENZINGA
Amicus Therapeutics` Opfolda (miglustat) Receives Approval in Europe
07 Jul 2023 //
EMA
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda (miglustat)
26 Apr 2023 //
GLOBENEWSWIRE
Amicus’ Therapy Gets Positive CHMP Opinion To Treat Pompe Disease
17 Dec 2022 //
NASDAQ
Breckenbridge`s Generic Miglustat Receives Approval in the U.S.
03 Feb 2022 //
FDA
Orphazyme’s arimoclomol expected to be used with Zavesca after likely FDA
22 Jan 2021 //
PHARMACEUTICAL-TECHNOLOGY
Edenbridge Pharms`s Generic Miglustat Receives Approval in US
10 Aug 2020 //
FDA
Orphazyme plans to pitch subgroup analyses of key study to regulators
31 Jan 2019 //
ENDPTS
Meeting highlights from the CHMP 10-13 December 2018
14 Dec 2018 //
Cerdelga (eliglustat) : Genzyme vs. Apotex
24 Nov 2018 //
PATENT LITIGATION
Amerigen Pharma`s Generic Miglustat Receives Approval In US
20 Apr 2018 //
FDA
JensonR+ Limited Yargesa (miglustat) Receives Approval In Europe
10 Apr 2017 //
EMA
Dipharma announces the validation of disanit® (nitisinone) marketing authorization application in Europe
23 Feb 2017 //
PRESS RELEASE
Eight medicines leap towards EU approval
30 Jan 2017 //
PHARMATIMES
Seven new therapies jump towards EU approval
04 Apr 2016 //
PHARMATIMES
AMERIGEN and DIPHARMA announce first regulatory submission for Miglustat 100mg Capsules
21 Mar 2016 //
PR NEWSWIRE
AMERIGEN and DIPHARMA announce first regulatory submission for Miglustat
11 Jan 2016 //
PR NEWS WIRE
Sanofi rare disease drug a breakthrough, says FDA
04 Jun 2015 //
PM LIVE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.